New PET tracer may reveal hidden cancer targets

NCT ID NCT07577206

Recruiting now Diagnosis Sponsor: National Cancer Institute, Naples Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a single dose of a new radioactive tracer called [68Ga]Ga-R54, which attaches to a protein (CXCR4) found on some cancer cells. Ten adults with advanced solid tumors or multiple myeloma will receive the tracer and then have a PET/CT scan to see where it goes in the body. The goal is to measure how well the tracer binds to tumors and how it moves through the blood, which could help improve cancer imaging in the future.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR MULTIPLE MYELOMA

Contacts and locations

Locations

Istituto Nazionale Tumori Fondazione G. Pascale - SC Medicina Nucleare e Terapia Metabolica
RECRUITING

Naples, Italia, 80131, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.